The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA 2019 | Real-world data from the first French cohort of patients treated with CAR T-cell therapy

Jun 24, 2019

At the 24th Congress of the European Hematology Association (EHA), Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, reports on the first French patients treated with CAR T.

These patients were treated on a compassionate programme and all had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Having enrolled 60 patients in 5 centers, 53 were treated due to early progression in 7 patients.

Professor Thieblemont notes the very promising results of these patients in relation to progression-free survival and an overall survival rate at 3 months of 80%.

Real-world data from the first French cohort of patients treated with CAR T-cell therapy